Parkinson Disease (PD)TECAR-PDNCT07842926
Acute Effects of Capacitive-Resistive Radiofrequency Therapy in People With Parkinson's Disease
A study testing Capacitive Radiofrequency Therapy, Resistive Radiofrequency Therapy and Capacitive-Resistive Radiofrequency Therapy in people with Parkinson Disease (PD), run by Universidad San Jorge at 1 site in Spain.
Trial summary
This study will investigate the immediate and short-term effects of capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs in people with Parkinson's disease. Read more about this study
- Who is it for?
- Ages 55 to 90 years
- Conditions the study is for
- Parkinson Disease (PD)
- What is being tested?
- Capacitive Radiofrequency Therapy, Resistive Radiofrequency Therapy and Capacitive-Resistive Radiofrequency Therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteSpain
- Study dates
- 21 Sep 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age between 55 and 90 years. Clinical diagnosis of idiopathic Parkinson's disease confirmed by a Neurology specialist.
- Hoehn and Yahr stage II or III. Functional walking ability. Clinically relevant lower-limb rigidity in at least one leg, defined as a score ≥2 on item 3.3d (right lower limb) or 3.3e (left lower limb) of Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
- Stable antiparkinsonian pharmacological treatment during the previous 4 weeks, with no planned changes during the intervention period.
- Ability to understand and follow simple instructions, defined as a score >24 on the validated Spanish version of the Mini-Mental State Examination (MMSE-MEC).
- Provision of written informed consent.
Who cannot join
- Advanced Parkinson's disease, defined as Hoehn and Yahr stage >III, with severe postural instability.
- Other neurological or musculoskeletal conditions that could interfere with the assessment of lower-limb rigidity or gait.
- Skin lesions, open wounds, or infection in the area where radiofrequency therapy will be applied.
- Presence of a pacemaker, defibrillator, other implanted electronic device, or another contraindication to TECAR therapy, such as altered thermal sensitivity.
- Lower-limb surgery within the previous 6 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Asociación Parkinson Aragón
Zaragoza, Zaragoza, 50015
Paula Cordova-Alegre, PhD, +34605245894, pcordova@usj.es
About this study
Official title: Safety, Tolerability, and Acute Effects of Capacitive-Resistive Radiofrequency Therapy (TECAR) Applied to the Lower Limbs in People With Parkinson's Disease: An Experimental Within-Subject Study
This study will investigate the immediate and short-term effects of capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs in people with Parkinson's disease. The main aim is to determine which of four different TECAR application protocols produces the greatest improvement in muscle stiffness and walking function.
Twenty participants with Parkinson's disease will receive four different TECAR protocols in four separate sessions. The protocols will include capacitive treatment, resistive treatment, and two combinations of capacitive and resistive treatment. Each participant will receive all four protocols, and the order in which they are applied will be randomized. Sessions will be separated by a 7-day washout period.
Read more
Muscle stiffness will be measured using the MyotonPRO device. Walking and functional mobility will also be assessed using the Timed Up and Go test and the 10-Metre Walk Test. Joint range of motion and lower-limb musculoskeletal pain will also be evaluated. Measurements will be performed immediately before treatment, immediately after treatment, and 48 hours after each session.
The study will also record any discomfort or adverse events associated with TECAR therapy to evaluate the safety and tolerability of the different treatment protocols.
Read the detailed description
This is an experimental, randomized-sequence, within-subject crossover study designed to evaluate the safety, tolerability, and acute effects of capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs of people with Parkinson's disease.
Each participant will receive four TECAR treatment protocols in separate sessions: (1) capacitive mode for 15 minutes per leg; (2) resistive mode for 15 minutes per leg; (3) a mixed capacitive-resistive protocol consisting of 10 minutes of capacitive treatment followed by 5 minutes of resistive treatment per leg; and (4) a mixed resistive-capacitive protocol consisting of 10 minutes of resistive treatment followed by 5 minutes of capacitive treatment per leg. Treatment intensity will be individually adjusted to produce a clear but comfortable thermal effect.
The order of the four interventions will be randomized individually for each participant to minimize potential period, learning, and carryover effects. A washout period of at least 7 days will separate treatment sessions. Participants will continue their usual antiparkinsonian medication and usual medical care throughout the study. Assessments will be performed during the pharmacological "ON" state, approximately 60-90 minutes after the participant's usual dopaminergic medication.
The primary outcome will be lower-limb muscle stiffness measured objectively using MyotonPRO myotonometry. Measurements will be obtained from standardized anatomical sites, including the medial gastrocnemius, tibialis anterior, rectus femoris, and biceps femoris muscles.
Secondary outcomes will include functional mobility assessed with the Timed Up and Go test, walking speed assessed with the 10-Metre Walk Test, range of motion of the ankle, knee, and hip measured by goniometry, and lower-limb musculoskeletal pain assessed using a Numeric Rating Scale.
Outcomes will be assessed immediately before each intervention, immediately after each intervention, and 48 hours after each treatment session. Adverse events and treatment-related discomfort will also be recorded during each intervention and at the 48-hour assessment to evaluate the safety and tolerability of the different TECAR protocols.
The study plans to recruit 20 participants with idiopathic Parkinson's disease, Hoehn and Yahr stages II-III, who have functional walking ability and clinically relevant lower-limb rigidity.
- Conditions
- Parkinson Disease (PD)
- Being tested
- Capacitive Radiofrequency Therapy, Resistive Radiofrequency Therapy, Capacitive-Resistive Radiofrequency Therapy, Resistive-Capacitive Radiofrequency Therapy
- Keywords
- Capacitive-Resistive Radiofrequency Therapy, TECAR Therapy, Myotonometry, Physical Therapy, Muscle Stiffness, Rehabilitation
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Capacitive Radiofrequency TherapyOther
Capacitive-resistive radiofrequency therapy (TECAR) will be applied in capacitive mode to the lower limbs for 15 minutes per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale.
Resistive Radiofrequency TherapyOther
Capacitive-resistive radiofrequency therapy (TECAR) will be applied in resistive mode to the lower limbs for 15 minutes per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale.
Capacitive-Resistive Radiofrequency TherapyOther
Capacitive-resistive radiofrequency therapy (TECAR) will be applied to the lower limbs using a mixed protocol consisting of 10 minutes of capacitive treatment followed by 5 minutes of resistive treatment per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale.
Resistive-Capacitive Radiofrequency TherapyOther
Capacitive-resistive radiofrequency therapy (TECAR) will be applied to the lower limbs using a mixed protocol consisting of 10 minutes of resistive treatment followed by 5 minutes of capacitive treatment per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale.
| Study group | Role | What they receive |
|---|---|---|
| Capacitive TECAR Therapy | Experimental | Participants will receive capacitive-resistive radiofrequency therapy (TECAR) applied in capacitive mode to the lower limbs for 15 minutes per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Treatment intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. Receives: Other: Capacitive Radiofrequency Therapy |
| Resistive TECAR Therapy | Experimental | Participants will receive capacitive-resistive radiofrequency therapy (TECAR) applied in resistive mode to the lower limbs for 15 minutes per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Treatment intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. Receives: Other: Resistive Radiofrequency Therapy |
| Capacitive-Resistive TECAR Therapy | Experimental | Participants will receive capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs using a mixed protocol consisting of 10 minutes of capacitive treatment followed by 5 minutes of resistive treatment per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Treatment intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. Receives: Other: Capacitive-Resistive Radiofrequency Therapy |
| Resistive-Capacitive TECAR Therapy | Experimental | Participants will receive capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs using a mixed protocol consisting of 10 minutes of resistive treatment followed by 5 minutes of capacitive treatment per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Treatment intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale Receives: Other: Resistive-Capacitive Radiofrequency Therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Lower-Limb Muscle Stiffness
Lower-limb muscle stiffness will be assessed using the MyotonPRO device and expressed in N/m. Three consecutive measurements will be performed at standardized anatomical sites on the medial gastrocnemius, tibialis anterior, rectus femoris, and biceps femoris muscles, and the mean value will be used for analysis.
Measured: Immediately before, immediately after, and 48 hours after each intervention session
Secondary outcomes (5)
Change in Functional Mobility Assessed With the Timed Up and Go Test
Functional mobility will be assessed using the Timed Up and Go (TUG) test. The time required to stand up from a chair, walk 3 meters, turn around, walk back, and sit down will be recorded in seconds. Three attempts will be performed, and the best result will be used for analysis.
Measured: Immediately before, immediately after, and 48 hours after each intervention session
Change in Gait Speed Assessed With the 10-Metre Walk Test
Gait speed will be assessed using the 10-Metre Walk Test (10MWT) at a comfortable walking speed. Walking speed will be expressed in meters per second (m/s). Three attempts will be performed, and the best result will be used for analysis.
Measured: Immediately before, immediately after, and 48 hours after each intervention session
Change in Lower-Limb Joint Range of Motion
Range of motion of the ankle, knee, and hip will be assessed using a universal goniometer and expressed in degrees. Two measurements will be performed for each assessment, and the mean value will be used for analysis.
Measured: Immediately before, immediately after, and 48 hours after each intervention session
Change in Lower-Limb Musculoskeletal Pain
Lower-limb musculoskeletal pain will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Pain will be evaluated in relation to lower-limb movement and functional assessment.
Measured: Immediately before, immediately after, and 48 hours after each intervention session
Incidence of Treatment-Related Adverse Events
Safety and tolerability will be assessed by recording adverse events and treatment-related discomfort, including increased pain, excessive or intolerable heat, persistent erythema, skin burns or blisters, dizziness, malaise, increased fatigue, gait instability, or any other symptoms occurring during or following the intervention.
Measured: During each intervention session and up to 48 hours after each intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start21 Sep 2026 (estimated)
- Primary completion1 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson Disease (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universidad San Jorge
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07842926
- Sponsor's protocol ID
- committee approval:PI26/280
- Acronym
- TECAR-PD
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly shared because the approved study protocol does not include a specific plan for sharing individual-level data with external researchers. Study results will be reported in aggregated form to protect participant confidentiality and privacy.
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety, Tolerability, and Acute Effects of Capacitive-Resistive Radiofrequency Therapy (TECAR) Applied to the Lower Limbs in People With Parkinson's Disease: An Experimental Within-Subject Study
- ClinicalTrials.gov ID
- NCT07842926
- Acronym / sponsor ID
- TECAR-PD / committee approval:PI26/280
- Conditions
- Parkinson Disease (PD)
- Keywords
- Capacitive-Resistive Radiofrequency Therapy, TECAR Therapy, Myotonometry, Physical Therapy, Muscle Stiffness, Rehabilitation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Universidad San JorgeUniversity, hospital or other
- Study start
- 21 Sep 2026 (estimated)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 25 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will investigate the immediate and short-term effects of capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs in people with Parkinson's disease. The main aim is to determine which of four different TECAR application protocols produces the greatest improvement in muscle stiffness and walking function.
Twenty participants with Parkinson's disease will receive four different TECAR protocols in four separate sessions. The protocols will include capacitive treatment, resistive treatment, and two combinations of capacitive and resistive treatment. Each participant will receive all four protocols, and the order in which they are applied will be randomized. Sessions will be separated by a 7-day washout period.
Muscle stiffness will be measured using the MyotonPRO device. Walking and functional mobility will also be assessed using the Timed Up and Go test and the 10-Metre Walk Test. Joint range of motion and lower-limb musculoskeletal pain will also be evaluated. Measurements will be performed immediately before treatment, immediately after treatment, and 48 hours after each session.
The study will also record any discomfort or adverse events associated with TECAR therapy to evaluate the safety and tolerability of the different treatment protocols.
Detailed description
This is an experimental, randomized-sequence, within-subject crossover study designed to evaluate the safety, tolerability, and acute effects of capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs of people with Parkinson's disease.
Each participant will receive four TECAR treatment protocols in separate sessions: (1) capacitive mode for 15 minutes per leg; (2) resistive mode for 15 minutes per leg; (3) a mixed capacitive-resistive protocol consisting of 10 minutes of capacitive treatment followed by 5 minutes of resistive treatment per leg; and (4) a mixed resistive-capacitive protocol consisting of 10 minutes of resistive treatment followed by 5 minutes of capacitive treatment per leg. Treatment intensity will be individually adjusted to produce a clear but comfortable thermal effect.
The order of the four interventions will be randomized individually for each participant to minimize potential period, learning, and carryover effects. A washout period of at least 7 days will separate treatment sessions. Participants will continue their usual antiparkinsonian medication and usual medical care throughout the study. Assessments will be performed during the pharmacological "ON" state, approximately 60-90 minutes after the participant's usual dopaminergic medication.
The primary outcome will be lower-limb muscle stiffness measured objectively using MyotonPRO myotonometry. Measurements will be obtained from standardized anatomical sites, including the medial gastrocnemius, tibialis anterior, rectus femoris, and biceps femoris muscles.
Secondary outcomes will include functional mobility assessed with the Timed Up and Go test, walking speed assessed with the 10-Metre Walk Test, range of motion of the ankle, knee, and hip measured by goniometry, and lower-limb musculoskeletal pain assessed using a Numeric Rating Scale.
Outcomes will be assessed immediately before each intervention, immediately after each intervention, and 48 hours after each treatment session. Adverse events and treatment-related discomfort will also be recorded during each intervention and at the 48-hour assessment to evaluate the safety and tolerability of the different TECAR protocols.
The study plans to recruit 20 participants with idiopathic Parkinson's disease, Hoehn and Yahr stages II-III, who have functional walking ability and clinically relevant lower-limb rigidity.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Capacitive TECAR Therapy | Experimental | Other: Capacitive Radiofrequency TherapyParticipants will receive capacitive-resistive radiofrequency therapy (TECAR) applied in capacitive mode to the lower limbs for 15 minutes per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Treatment intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. |
| Resistive TECAR Therapy | Experimental | Other: Resistive Radiofrequency TherapyParticipants will receive capacitive-resistive radiofrequency therapy (TECAR) applied in resistive mode to the lower limbs for 15 minutes per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Treatment intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. |
| Capacitive-Resistive TECAR Therapy | Experimental | Other: Capacitive-Resistive Radiofrequency TherapyParticipants will receive capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs using a mixed protocol consisting of 10 minutes of capacitive treatment followed by 5 minutes of resistive treatment per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Treatment intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. |
| Resistive-Capacitive TECAR Therapy | Experimental | Other: Resistive-Capacitive Radiofrequency TherapyParticipants will receive capacitive-resistive radiofrequency therapy (TECAR) applied to the lower limbs using a mixed protocol consisting of 10 minutes of resistive treatment followed by 5 minutes of capacitive treatment per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Treatment intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale |
Who may qualify
- Ages
- 55 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age between 55 and 90 years. Clinical diagnosis of idiopathic Parkinson's disease confirmed by a Neurology specialist.
- Hoehn and Yahr stage II or III. Functional walking ability. Clinically relevant lower-limb rigidity in at least one leg, defined as a score ≥2 on item 3.3d (right lower limb) or 3.3e (left lower limb) of Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
- Stable antiparkinsonian pharmacological treatment during the previous 4 weeks, with no planned changes during the intervention period.
- Ability to understand and follow simple instructions, defined as a score >24 on the validated Spanish version of the Mini-Mental State Examination (MMSE-MEC).
- Provision of written informed consent.
Key exclusion criteria (5 listed)
- Advanced Parkinson's disease, defined as Hoehn and Yahr stage >III, with severe postural instability.
- Other neurological or musculoskeletal conditions that could interfere with the assessment of lower-limb rigidity or gait.
- Skin lesions, open wounds, or infection in the area where radiofrequency therapy will be applied.
- Presence of a pacemaker, defibrillator, other implanted electronic device, or another contraindication to TECAR therapy, such as altered thermal sensitivity.
- Lower-limb surgery within the previous 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Capacitive Radiofrequency TherapyCapacitive-resistive radiofrequency therapy (TECAR) will be applied in capacitive mode to the lower limbs for 15 minutes per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. | Other | Capacitive TECAR Therapy |
| Resistive Radiofrequency TherapyCapacitive-resistive radiofrequency therapy (TECAR) will be applied in resistive mode to the lower limbs for 15 minutes per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. | Other | Resistive TECAR Therapy |
| Capacitive-Resistive Radiofrequency TherapyCapacitive-resistive radiofrequency therapy (TECAR) will be applied to the lower limbs using a mixed protocol consisting of 10 minutes of capacitive treatment followed by 5 minutes of resistive treatment per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. | Other | Capacitive-Resistive TECAR Therapy |
| Resistive-Capacitive Radiofrequency TherapyCapacitive-resistive radiofrequency therapy (TECAR) will be applied to the lower limbs using a mixed protocol consisting of 10 minutes of resistive treatment followed by 5 minutes of capacitive treatment per leg. Treatment will target the posterior lower leg, quadriceps, and hamstring muscle regions. Intensity will be individually adjusted to a medium-high level producing a clear but comfortable thermal effect, approximately 3-4 out of 5 on the device intensity scale. | Other | Resistive-Capacitive TECAR Therapy |
Primary outcome
Change in Lower-Limb Muscle Stiffness
Time frame: Immediately before, immediately after, and 48 hours after each intervention session
Lower-limb muscle stiffness will be assessed using the MyotonPRO device and expressed in N/m. Three consecutive measurements will be performed at standardized anatomical sites on the medial gastrocnemius, tibialis anterior, rectus femoris, and biceps femoris muscles, and the mean value will be used for analysis.
5 secondary outcomes
Change in Functional Mobility Assessed With the Timed Up and Go Test
Time frame: Immediately before, immediately after, and 48 hours after each intervention session
Change in Gait Speed Assessed With the 10-Metre Walk Test
Time frame: Immediately before, immediately after, and 48 hours after each intervention session
Change in Lower-Limb Joint Range of Motion
Time frame: Immediately before, immediately after, and 48 hours after each intervention session
Change in Lower-Limb Musculoskeletal Pain
Time frame: Immediately before, immediately after, and 48 hours after each intervention session
Incidence of Treatment-Related Adverse Events
Time frame: During each intervention session and up to 48 hours after each intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly shared because the approved study protocol does not include a specific plan for sharing individual-level data with external researchers. Study results will be reported in aggregated form to protect participant confidentiality and privacy.
Related trials for Parkinson Disease (PD)
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Capacitive Radiofrequency Therapy, Resistive Radiofrequency Therapy and Capacitive-Resistive Radiofrequency Therapy in people with Parkinson Disease (PD), run by Universidad San Jorge at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Paula Cordova-Alegre, PhD (+34605245894, pcordova@usj.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Lower-Limb Muscle Stiffness (time frame: Immediately before, immediately after, and 48 hours after each intervention session). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.